Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT06002425
Recruiting Not applicable

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

NCT06002425 · tracked via the Priya Life Science Germany tracker
Sponsor
Chinese Academy of Sciences
Phase
Not applicable
Started
2023-08-29
Last updated
2023-09-08

Condition(s) studied

Gastrointestinal Neoplasm Malignant

Investigational drug(s) / intervention(s)

Clinician-Directed Treatment PlanChatGPT-Assisted Treatment Plan

Clinician-Directed Treatment Plan: In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.

ChatGPT-Assisted Treatment Plan: In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.

Study summary

This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years, both male and female. * Pathologically confirmed diagnosis of gastrointestinal cancer (gastric cancer or colorectal Cancer). * Detailed medical records available prior to treatment (including chief complaint, history of present illness, radiological examinations, pathological examinations, laboratory tests, etc.). * Participants will receive complete treatment in the participating hospitals. Exclusion Criteria: * Participants with cancers other than gastrointestinal cancers. * Participants who receive treatment in multiple hospitals.

Primary outcome measure(s)

  • Influence Rate of ChatGPT on Treatment Plans — Within 24 hours after the treatment plan is determined from the onset of study participation.
    The percentage of the initial 100 participants and the overall participants in the ChatGPT-Assisted group whose treatment plans are adjusted by clinicians after consulting with ChatGPT.

Trial sites (7)

FacilityCityRegionStatus
City of Hope Duarte California Not Yet Recruiting
Jiangmen Central Hospital Jiangmen Guangdong Recruiting
The Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai Guangdong Recruiting
Zhuhai People's Hospital Zhuhai Guangdong Recruiting
Peking University Cancer Hospital (Inner Mongolia Campus) Hohhot Inner Mongolia Recruiting
University Hospital Magdeburg Magdeburg Saxony-Anhalt Not Yet Recruiting
San Raffaele University Hospital, Italy Milan Italy Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06002425 on ClinicalTrials.gov ↗ ← All trials in Germany